The Financial Post reports in its Wednesday edition that Bloom Burton & Co. analyst David Martin says investors may want to keep an eye on biopharma Aurinia Pharmaceuticals ($8.68). The Post's Victor Ferreira quotes Mr. Martin saying that Victoria-based Aurinia is developing a drug called Voclosporin to treat lupus nephritis, and while it looked promising, its phase 2b results were mixed. The standard, Mr. Martin said, is that only 10 to 20 per cent of patients fully remit from lupus nephritis, a disease where the kidneys become inflamed due to the immune system misfiring and attacking healthy tissue. Voclosporin works as an immune system suppressor and boosted remission rates to 40 to 50 per cent during its phase 2b trial. Offsetting the positive results was the news that 13 deaths occurred during the trial. An investigation determined none of the deaths were related to Voclosporin. The stock, however, fell to $8.04 from $10.38 after the results were announced in January last year and has not reached the same level since. Aurinia is expected to announce phase 3 results at the end of the year. Over all, Mr. Martin warned generalists looking to dip into the sector that, "You really have to know the science."